











A thesis submitted for the 
Degree of Doctor of Philosophy (Science) 







Certificate of original authorship 
 
 
I certify that the work in this thesis has not previously been submitted for a degree nor 
has it been submitted as part of requirements for a degree except as part of the 
collaborative doctoral degree and/or fully acknowledged within the text. 
  
I also certify that the thesis has been written by me. Any help that I have received in my 
research work and the preparation of the thesis itself has been acknowledged. In addition, 




























I would like to express my sincere gratitude to my supervisor Associate Professor Shanlin 
Fu for all your support and guidance. Your kind and cheerful manner was always 
encouraging and I would particularly like to thank you for the patience you had for me, 
which enabled me to finally reach the last stage of the challenging but rewarding journey. 
 
To my co-supervisor, Dr Unnikrishnan Kuzhiumparambil, I would like to thank you for 
your various support in the lab, outside the lab and outside the university. You have been 
my mentor for research and beyond.  
 
To the Swedish National Board of Forensic Medicine (Rättsmedicinalverket) and the 
Strategic Research Area Forensic Sciences (Strategiområdet Forensiska Vetenskaper) at 
Linköping University, particularly Dr Ariane Wohlfarth, Dr Robert Kronstrand, Dr 
Svante Vikingsson and Dr Henrik Green, I wish to thank you for the warm welcome in 
Sweden. The opportunity gave a whole new dimension to my project and enriched my 
cultural experience. 
 
I would like to thank Advanced Chemistry Development (ACD/Labs) for providing 
MetaSense™ software as well as Richard Lee and Edward Milton for their help. 
 
I thank you to all the academic and professional staff at UTS who supported me 
throughout my candidature. I wish to thank Jane Cameron and Zofia Winiarski for the 
support with the fungus study and allowing me the access to the incubation facility. Thank 
you to Dr Ronald Shimmon for providing the knowledge of synthetic techniques and 
support with the NMR and the laboratories. I also wish to thank Dr David Bishop and Dr 
Verena Taudte for the technical support with LC-MS instruments. 
 
To Mahmoud El Safadi, thank you for the support with the synthesis. To Dr Susan Luong 
and Dr Anna Molnar, thank you for the tips for LC-MS use and PhD life. I also wish to 
thank Daniel Pasin, Morgan Philp and the forensic toxicology research group for 






I would also like to thank Professor Claude Roux and Centre for Forensic Science for 
providing support, particularly with the attendance of conferences. 
 









The following publications are reproduced in this thesis with the permission from the 
publishers (1.  License Number, 4164621167361; 2. Creative Commons Attribution 
License (CC BY), https://creativecommons.org/licenses/by/4.0/; 3. License Number, 
4164631017507; 4. License Number, 4164640139178): 
 
For Chapter 2 
 
1. Watanabe S, Kuzhiumparambil U, Winiarski Z, Fu S. Biotransformation of 
synthetic cannabinoids JWH-018, JWH-073 and AM2201 by Cunninghamella 
elegans. Forensic Sci Int. 2016;261:33-42. 
doi:http://dx.doi.org/10.1016/j.forsciint.2015.12.023. 
 
2. Watanabe S, Kuzhiumparambil U, Winiarski Z, Fu S. Data on individual 
metabolites of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by 
Cunninghamella elegans. Data Brief. 2016;7:332-40. 
doi:10.1016/j.dib.2016.02.039. 
 
For Chapter 3 
 
3. Watanabe S, Kuzhiumparambil U, Nguyen MA, Cameron J, Fu S. Metabolic 
Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by 
Cunninghamella elegans. AAPS Journal. 2017;19(4):1148-62. 
doi:10.1208/s12248-017-0078-4. 
 
For Chapter 6 
 
4. Watanabe S, Vikingsson S, Roman M, Green H, Kronstrand R, Wohlfarth A. 
In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic 
Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-
Isobutyrylfentanyl. AAPS Journal. 2017;19(4):1102-22. doi:10.1208/s12248-
017-0070-z. 
 
Table of Contents  
vi 
 
Table of Contents 
 
Certificate of original authorship ............................................................................................... ii 
Acknowledgments ....................................................................................................................... iii 
Publications .................................................................................................................................. v 
List of figures .............................................................................................................................. xi 
List of tables ...............................................................................................................................xiv 
Abstract ..................................................................................................................................... xvii 
Chapter 1: Introduction .............................................................................................................. 1 
1.1 New Psychoactive Substances ........................................................................................... 2 
1.1.1 Synthetic cannabinoids ............................................................................................... 3 
1.1.2 Fentanyl analogues ..................................................................................................... 7 
1.2 Metabolism ......................................................................................................................... 8 
1.2.1 Metabolism models ..................................................................................................... 8 
1.2.2 Metabolism studies ................................................................................................... 10 
1.2.2.1 JWH-018 .............................................................................................................. 10 
1.2.2.2 JWH-073 .............................................................................................................. 11 
1.2.2.3 JWH-081 .............................................................................................................. 11 
1.2.2.4 JWH-122 .............................................................................................................. 12 
1.2.2.5 JWH-210 .............................................................................................................. 12 
1.2.2.6 JWH-250 .............................................................................................................. 12 
1.2.2.7 HU-210 ................................................................................................................ 12 
1.2.2.8 RCS-4 ................................................................................................................... 12 
1.2.2.9 AM2201 and UR-144 ........................................................................................... 13 
1.2.2.10 Potential common metabolite ............................................................................ 13 
1.3 Instruments ...................................................................................................................... 15 
1.3.1 Liquid chromatography – mass spectrometry ....................................................... 15 
1.3.2 Nuclear magnetic resonance spectroscopy ............................................................. 15 
1.3.3 Detection of synthetic cannabinoids and their metabolites ................................... 16 
1.4 Aims of this project ......................................................................................................... 18 
1.4 References ........................................................................................................................ 20 
Chapter 2: Biotransformation of synthetic cannabinoids JWH-018, JWH-073 and 
AM2201 by Cunninghamella elegans ....................................................................................... 30 
Table of Contents  
vii 
 
2.1 Abstract ............................................................................................................................ 31 
2.2 Introduction ..................................................................................................................... 33 
2.3 Materials and Methods ................................................................................................... 35 
2.3.1 Chemicals .................................................................................................................. 35 
2.3.2 Microbial Culture and Biotransformation Conditions ......................................... 35 
2.3.3 Extraction, Isolation, and Identification of Metabolites ....................................... 36 
2.4 Results .............................................................................................................................. 38 
2.4.1 JWH-018 ................................................................................................................... 40 
2.4.2 JWH-073 ................................................................................................................... 41 
2.4.3 AM2201 ..................................................................................................................... 45 
2.5 Discussion......................................................................................................................... 49 
2.6 Conclusion ....................................................................................................................... 53 
2.7 References ........................................................................................................................ 54 
2.8. Appendices ...................................................................................................................... 59 
Chapter 3: Metabolic profile of synthetic cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-
144 by Cunninghamella elegans ............................................................................................... 75 
3.1 Abstract ............................................................................................................................ 76 
3.2 Introduction ..................................................................................................................... 78 
3.3 Materials and Methods ................................................................................................... 81 
3.3.1 Chemicals and reagents ........................................................................................... 81 
3.3.2 Biotransformation by fungus and sample preparation ........................................ 81 
3.3.3 LC-QTOF analysis ................................................................................................... 82 
3.3.4 LC-QqQ analysis ...................................................................................................... 83 
3.4 Results .............................................................................................................................. 84 
3.4.1 5F-PB-22 ................................................................................................................... 84 
3.4.2 PB-22 ......................................................................................................................... 84 
3.4.3 XLR-11 ...................................................................................................................... 90 
3.4.4 UR-144 ...................................................................................................................... 93 
3.5 Discussion......................................................................................................................... 96 
3.5.1 Metabolite identification .......................................................................................... 96 
3.5.1.1 5F-PB-22 ............................................................................................................. 96 
3.5.1.2 PB-22 .................................................................................................................. 97 
3.5.1.3 XLR-11 ................................................................................................................ 99 
3.5.1.4 UR-144 .............................................................................................................. 101 
3.5.2 Comparison of fungal metabolites with reported human metabolites .............. 102 
Table of Contents  
viii 
 
3.5.3 Comparison of fungal model with in vitro human models .................................. 104 
3.6 Conclusion ...................................................................................................................... 106 
3.7 References ...................................................................................................................... 107 
3.8. Appendices .................................................................................................................... 114 
Chapter 4: Structural elucidation of metabolites of synthetic cannabinoid UR-144 by 
Cunninghamella elegans using nuclear magnetic resonance spectroscopy ........................ 121 
4.1 Abstract .............................................................................................................................. 122 
4.2 Introduction ....................................................................................................................... 124 
4.3 Materials and methods ...................................................................................................... 127 
4.3.1 Chemicals and reagents .......................................................................................... 127 
4.3.2 Fungus metabolite characterisation ...................................................................... 127 
4.3.2.1 Fungus incubation ............................................................................................. 127 
4.3.2.2 Preparative high performance liquid chromatography (HPLC) ....................... 127 
4.3.2.3 NMR spectroscopy ............................................................................................. 128 
4.3.2.4 Liquid chromatography – quadrupole time-of-flight mass spectrometry (LC-
QTOF-MS) ..................................................................................................................... 128 
4.3.3 HLM metabolite characterisation ......................................................................... 129 
4.3.3.1 HLM incubation ................................................................................................. 129 
4.3.3.2 LC-QTOF-MS .................................................................................................... 129 
4.4 Results ................................................................................................................................. 130 
4.4.1 Fungus metabolite characterisation ...................................................................... 130 
4.4.1.1 NMR analysis ..................................................................................................... 131 
4.4.2 HLM metabolite characterisation ......................................................................... 131 
4.5 Discussion ........................................................................................................................... 136 
4.5.1 Fungus metabolite characterisation ...................................................................... 136 
4.5.1.1 NMR analysis ..................................................................................................... 136 
4.5.1.1.1 UR-144 ....................................................................................................... 136 
4.5.1.1.2 Dihydroxy metabolites M1-3 (U7) ............................................................. 136 
4.5.1.1.3 Hydroxy and ketone metabolite M7 (U14) ................................................. 138 
4.5.1.1.4 Carboxy and hydroxy metabolites M4-6 (U10) and M8-9 (U15) .............. 138 
4.5.1.1.5 Carboxy and ketone metabolite M10 (U17) ............................................... 139 
4.5.2 HLM metabolite characterisation ......................................................................... 140 
4.5.3 Advantages and disadvantages of the fungus metabolism .................................. 140 
4.6 Conclusion .......................................................................................................................... 142 
Table of Contents  
ix 
 
4.7 References .......................................................................................................................... 143 
Chapter 5: In vitro metabolism of synthetic cannabinoid AM1220 by human liver 
microsomes and Cunninghamella elegans using liquid chromatography coupled with high 
resolution mass spectrometry ................................................................................................ 146 
5.1 Abstract .......................................................................................................................... 147 
5.2 Introduction ................................................................................................................... 149 
5.3 Materials and Methods ................................................................................................. 151 
5.3.1 Chemicals and reagents ......................................................................................... 151 
5.3.2 Metabolic stability .................................................................................................. 151 
5.3.3 Metabolite identification ........................................................................................ 153 
5.3.3.1 Human liver microsomes incubation ................................................................ 153 
5.3.3.2 Fungus incubation............................................................................................. 153 
5.3.3.3 LC-QTOF-MS ................................................................................................... 153 
5.4 Results ............................................................................................................................ 155 
5.4.1 Metabolic stability .................................................................................................. 155 
5.4.2 Metabolite identification ........................................................................................ 155 
5.4.2.1 AM1220 identification by LC-QTOF-MS.......................................................... 157 
5.4.2.2 Human liver microsomes .................................................................................. 159 
5.4.2.3 Fungus C. elegans ............................................................................................. 159 
5.5 Discussion....................................................................................................................... 160 
5.5.1 Metabolic stability .................................................................................................. 160 
5.5.2 Metabolite identification ........................................................................................ 160 
5.5.2.1 Hydroxylation ................................................................................................... 160 
5.5.2.2 Dihydroxylation ................................................................................................ 161 
5.5.2.3 Dihydrodiol formation ...................................................................................... 161 
5.5.2.4 Demethylation ................................................................................................... 161 
5.5.2.5 Dihydrodiol formation and demethylation ........................................................ 162 
5.5.3 Comparison of AM1220 metabolites in HLM and C. elegans with in vivo human 
metabolites ....................................................................................................................... 162 
5.5.4 Suggested biomarkers ............................................................................................ 163 
5.6 Conclusion ..................................................................................................................... 164 
5.7 References ...................................................................................................................... 165 
Chapter 6: In vitro and in vivo metabolite identification studies for the new synthetic 
opioids acetylfentanyl, acrylfentanyl, furanylfentanyl, and 4-fluoro-isobutyrylfentanyl. 170 
6.1 Abstract .......................................................................................................................... 171 
Table of Contents  
x 
 
6.2 Introduction ................................................................................................................... 173 
6.3 Materials and Methods ................................................................................................. 175 
6.3.1 Chemicals and reagents .......................................................................................... 175 
6.3.2 Incubation with human hepatocytes and sample preparation ........................... 176 
6.3.3 Authentic human urine specimens and sample preparation .............................. 176 
6.3.4 LC-QTOF analysis ................................................................................................. 177 
6.3.5 Manual and software-assisted data analysis ........................................................ 177 
6.4 Results ............................................................................................................................. 179 
6.4.1 Metabolic profile of acetylfentanyl........................................................................ 179 
6.4.2 Metabolic profile of acrylfentanyl ......................................................................... 186 
6.4.3 Metabolic profile of 4-fluoro-isobutyrylfentanyl ................................................. 191 
6.4.4 Metabolic profile of furanylfentanyl ..................................................................... 191 
6.5 Discussion ....................................................................................................................... 201 
6.5.1 Structural elucidation of metabolites .................................................................... 201 
6.5.1.1 Acetylfentanyl metabolites ................................................................................. 201 
6.5.1.2 Acrylfentanyl metabolites .................................................................................. 204 
6.5.1.3 4-Fluoro-isobutyrylfentanyl metabolites ........................................................... 205 
6.5.1.4 Furanylfentanyl metabolites .............................................................................. 206 
6.5.2 How well did hepatocyte study results correlate with the findings in human 
urine samples? ................................................................................................................. 207 
6.5.3 Which metabolites are suitable analytical targets for urine analysis? .............. 208 
6.5.4 Is the metabolism of the new fentanyl analogues consistent with previous 
findings? ........................................................................................................................... 210 
6.6 Conclusion ...................................................................................................................... 211 
6.7 References ...................................................................................................................... 212 
6.8 Appendices ..................................................................................................................... 216 










List of figures 
 
Figure 1-1. Structures of some synthetic cannabinoids. 
Figure 2-1. Product ion spectra (CE 20 eV) and the proposed fragmentation pathways for 
JWH-018, JWH-073, AM2201 and their most abundant metabolites (Ma15, Mb13 and 
Mc25). 
Figure 2-2. Overlaid extracted ion chromatograms of all the metabolites identified in the 
fungus sample of JWH-018 at m/z 306, 340, 356, 358, 372, 374, 376, 390, 392 (a); JWH-
073 at m/z 306, 326, 342, 344, 358, 360, 362, 376, 378 (b); and AM2201 at m/z 306, 328, 
342, 358, 372, 374, 376, 388, 392, 394, 408, 410, 426, 472, 538, 554 (c). Only the major 
metabolites are labelled for AM2201 (c). 
Figure 2-3. Proposed metabolic pathway of JWH-018 in C. elegans. 
Figure 2-4. Proposed metabolic pathway of JWH-073 in C. elegans. 
Figure 2-5. Proposed metabolic pathway of AM2201 in C. elegans. Parentheses indicate 
intermediate metabolites that were not detected in the study. 
Figure 3-1. MS/MS spectra obtained with CE 20 eV and structures with the suggested 
fragmentation patterns and their exact masses for the parent drugs (5F-PB-22, PB-22, 
XLR-11 and UR-144) and their most abundant fungal metabolites based on peak area 
(F10, P13, X21 and U7). The exact position of the dihydrodiol structure within quinoline 
moiety in F10 is not determined. 
Figure 3-2. Combined extracted ion chromatograms of all metabolites and their 
respective parent drugs for (a) 5F-PB-22, (b) PB-22, (c) XLR-11, and (d) UR-144 after 
incubation with C. elegans. 
Figure 3-3. Proposed metabolic pathway of 5F-PB-22 by C. elegans. Blue colour denotes 
a Phase II metabolite. Parenthesis represents a possible intermediate metabolite that was 
not detected in the study. For the metabolites with dihydrodiol structure, only one possible 
isomer is shown as a representative. 
Figure 3-4. Proposed metabolic pathway of PB-22 by C. elegans. Blue colour denotes 
Phase II metabolites. Parentheses represent possible intermediate metabolites that were 




not detected in the study. For the metabolites with dihydrodiol structure, only one possible 
isomer is shown as a representative. 
Figure 3-5. Proposed metabolic pathway of XLR-11 by C. elegans. Blue colour denotes 
Phase II metabolites. 
Figure 3-6. Proposed metabolic pathway of UR-144 by C. elegans. 
Figure 4-1. The structures of UR-144 and the metabolites analysed in this study. Brackets 
indicate the metabolite ID in chapter 3 [14]. Arrows indicate partial metabolic pathways. 
M2 and M3, M5 and M6, and M8 and M9 are diastereomers, respectively, and share the 
same structures apart from the spatial configurations at the stereo centres. 
Figure 4-2. Preparative HPLC chromatogram showing separation of fractions 1-6. 
Fraction 2 and 3 partially coeluted. 
Figure 4-3. Gradient correlation spectroscopy (gCOSY), gradient heteronuclear multiple 
bond correlation (gHMBC) and selected nuclear overhauser effect (NOE) correlations of 
UR-144 and the metabolites analysed in the study. 
Figure 5-1. Combined extracted ion chromatograms of AM1220 and its metabolites in 
HLM and fungus incubation. 
Figure 5-2. MS/MS spectra of AM1220 and its metabolites at collision energy of 20 eV, 
and proposed metabolite structures with exact masses of fragmentation. Metabolites in 
brackets did not show all the product ions. The exact location of dihydrodiol is not 
determined. 
Figure 5-3. Proposed metabolic pathway of AM1220 in HLM and fungus C. elegans 
incubation in comparison with postmortem human data from the literature [10]. HP and 
HU refer to human plasma and human urine samples while asterisk indicates that the 
origin of the metabolite is not confirmed to be AM1220. The exact position of dihydrodiol 
is not determined. 
Figure 6-1. Structures of fentanyl and analogues that have approved medicinal use, others 
that have been abused for several decades, and those that appeared recently on the illicit 
drug market.  
Figure 6-2. Proposed metabolic pathway of acetylfentanyl combining both human 
hepatocyte and human urine metabolites. Markush structures are used where the exact 




position of functional groups cannot be determined. Enclosed metabolites are the major 
metabolites detected in hydrolysed human urine samples; metabolites in italics were only 
found in either the in vitro or in vivo experiment. 
Figure 6-3. Proposed metabolic pathway of acrylfentanyl combining both human 
hepatocyte and human urine metabolites. Markush structures are used where the exact 
position of functional groups cannot be determined. Enclosed metabolites are the major 
metabolites detected in hydrolysed human urine samples, metabolite in italics were only 
found in either the in vitro or in vivo experiment. 
Figure 6-4. Proposed metabolic pathway of 4-fluoro-isobutyrylfentanyl combining both 
human hepatocyte and human urine metabolites. Markush structures are used where the 
exact position of functional groups cannot be determined. Enclosed metabolites are the 
major metabolites detected in hydrolysed human urine samples, metabolite in italics were 
only found in either the in vitro or in vivo experiment. 
Figure 6-5. Proposed metabolic pathway of furanylfentanyl combining both human 
hepatocyte and human urine metabolites. Markush structures are used where the exact 
position of functional groups cannot be determined. Enclosed metabolites are the major 
metabolites detected in hydrolysed human urine samples, metabolite in italics were only 
found in either the in vitro or in vivo experiment. 
Supplementary Figure 6-1. MS/MS spectra and proposed fragmentation pattern of 
acetylfentanyl and its major metabolites in hydrolysed human urine samples. 
Supplementary Figure 6-2. MS/MS spectra and proposed fragmentation pattern of 
acrylfentanyl and its major metabolites in hydrolysed human urine samples. 
Supplementary Figure 6-3. MS/MS spectra and proposed fragmentation pattern of 4-
fluoroisobutyryllfentanyl and its major metabolites in hydrolysed human urine samples. 
Supplementary Figure 6-4. MS/MS spectra and proposed fragmentation pattern of 
furanylfentanyl and its major metabolites in hydrolysed human urine samples. 
 
 





List of tables 
 
Table 2-1. Metabolites of JWH-018 after C. elegans incubation in comparison with 
metabolites from other sources (human urine, human liver microsomes and rat urine) 
reported in literature, in alphabetical order. Square brackets in the metabolites column 
indicate the corresponding fungal metabolites in Fig. 2-3. 
Table 2-2. Metabolites of JWH-073 after C. elegans incubation in comparison with 
metabolites from other sources (human urine and human liver microsomes) reported in 
literature, in alphabetical order. Square brackets in the metabolites column indicate the 
corresponding fungal metabolites in Fig. 2-4. 
Table 2-3. Metabolites of AM2201 after C. elegans incubation in comparison with 
metabolites from other sources (human urine, human postmortem heart blood, human 
liver microsomes and rat urine) reported in literature, in alphabetical order. Square 
brackets in the metabolites column indicate the corresponding fungal metabolites in Fig. 
2-5. 
Supplementary Table 2-1. Metabolites of JWH-018 after C. elegans incubation. 
Supplementary Table 2-2. Key diagnostic product ions and their tentative structures 
used in elucidating biotransformation pathways of JWH-018 after C. elegans incubation. 
Supplementary Table 2-3. Metabolites of JWH-073 after C. elegans incubation. 
Supplementary Table 2-4. Key diagnostic product ions and their tentative structures 
used in elucidating biotransformation pathways of JWH-073 after C. elegans incubation. 
Supplementary Table 2-5. Metabolites of AM2201 after C. elegans incubation. 
Supplementary Table 2-6. Key diagnostic product ions and their tentative structures 
used in elucidating biotransformation pathways of AM2201 after C. elegans incubation. 
Square brackets indicate phase II metabolism. 
Table 3-1. Comparison of 5F-PB-22 metabolites formed by fungus, Cunninghamella 
elegans, with those by human hepatocytes and human liver microsomes reported in 
literature. 




Table 3-2. Comparison of PB-22 metabolites formed by fungus, Cunninghamella elegans, 
with those by human hepatocytes and human liver microsomes reported in literature. 
Table 3-3. Comparison of XLR-11 metabolites formed by fungus, Cunninghamella 
elegans, with those in human urine and human liver microsomes reported in literature. 
Table 3-4. Comparison of UR-144 metabolites formed by fungus, Cunninghamella 
elegans, with those in human urine and human liver microsomes reported in literature. 
Supplementary Table 3-1. 5F-PB-22 metabolites with retention time, elemental 
composition, exact mass, accurate mass, mass error and diagnostic product ions. 
Supplementary Table 3-2. PB-22 metabolites with retention time, elemental 
composition, exact mass, accurate mass, mass error and diagnostic product ions. 
Supplementary Table 3-3. XLR-11 metabolites with retention time, elemental 
composition, exact mass, accurate mass, mass error and diagnostic product ions. 
Supplementary Table 3-4. UR-144 metabolites with retention time, elemental 
composition, exact mass, accurate mass, mass error and diagnostic product ions. 
Table 4-1. 1H and 13C NMR data for UR-144 and fraction 1 containing dihydroxy 
metabolites (M1-3) in CDCl3. 
Table 4-2. 1H and 13C NMR data for carboxy and hydroxy metabolites (M4-6 and M8-9) 
in CDCl3. 
Table 4-3. 1H and 13C NMR data for a hydroxy and ketone metabolite (M7) and a carboxy 
and ketone metabolite (M10) in CDCl3. 
Table 5-1. AM1220 metabolites after HLM and fungus C. elegans incubation. 
Table 6-1. Acetylfentanyl metabolites with proposed biotransformation, retention time, 
elemental composition, accurate mass of protonated molecule, mass error of proposed 
metabolite, MS peak areas in hepatocyte samples (0h, 1h, 3h and 5h) and in five urine 
samples (hydrolysed and non-hydrolysed), and diagnostic product ions (masses and mass 
errors  taken from sample #3, and #5 in case of saturation). 
Table 6-2. Acrylfentanyl metabolites with proposed biotransformation, retention time, 
elemental composition, accurate mass of protonated molecule, mass error of proposed 
metabolite, MS peak areas in hepatocyte samples (0h, 1h, 3h and 5h) and in five urine 




samples (hydrolysed and non-hydrolysed), and diagnostic product ions (masses and mass 
errors generally taken from sample #3, except for B12 (#2), B1 and B14 (#5) and B10 
(hepatocytes). 
Table 6-3. 4-Fluoro-isobutyrylfentanyl metabolites with proposed biotransformation, 
retention time, elemental composition, accurate mass of protonated molecule, mass error 
of proposed metabolite, MS peak areas in hepatocyte samples (0h, 1h, 3h and 5h) and in 
five urine samples (hydrolysed and non-hydrolysed), and diagnostic product ions (masses 
and mass errors generally taken from sample #3, except for C2 (#1) and C8, C14, C16 
and C17 (hepatocytes). 
Table 6-4. Furanylfentanyl metabolites with proposed biotransformation, retention time, 
elemental composition, accurate mass of protonated molecule, mass error of proposed 
metabolite, MS peak areas in hepatocyte samples (0h, 1h, 3h and 5h) and in five urine 
samples (hydrolysed and non-hydrolysed), and diagnostic product ions (masses and mass 











The rapid and continuous emergence of new psychoactive substances has been a trend of 
the recreational drug market over the last decade. The sheer number of the new drugs has 
posed a challenge for the forensic and clinical laboratories to detect the consumption of 
the drugs in urine drug testing, especially when the metabolism of the drugs is unknown. 
This thesis aims to demonstrate that the fungus Cunninghamella elegans is a suitable 
model for metabolism studies of synthetic cannabinoids, as well as to provide new 
knowledge on metabolism of several new psychoactive substances to aid the forensic and 
clinical laboratories in detection of these drugs in urine testing. 
 
Seven synthetic cannabinoids JWH-018, JWH-073, AM2201, 5F-PB-22, PB-22, XLR-
11 and UR-144 were incubated with C. elegans for 72 h and the obtained metabolites 
were analysed by liquid chromatography–high resolution mass spectrometry (LC-HRMS). 
The cannabinoids underwent various biotransformations including, either alone or in 
combination, carboxylation, defluorination, dehydrogenation, demethylation, 
dihydrodiol formation, dihydroxylation, ester hydrolysis, hydroxylation, ketone 
formation, N-dealkylation, oxidative defluorination, oxidative defluorination to 
carboxylic acid, and trihydroxylation. Glucosidation and sulfation were the observed 
phase II biotransformations, although uncommon. The fungal metabolites were generally 
consistent with the human-relevant metabolites of these drugs reported in literature, 
except that glucuronidation is the common phase II human metabolic pathway instead of 
glucosidation and that the prevalence of the fungal metabolites was not always reflective 
of the human metabolite prevalence. 
 
Large amounts of fungal metabolites of UR-144 were obtained in an upscaled experiment 
and analysed by nuclear magnetic resonance (NMR) spectroscopy after isolating several 
metabolites by preparative high performance liquid chromatography (HPLC). Ten 
metabolites were characterised including dihydroxy metabolites, carboxy and hydroxy 
metabolites, a hydroxy and ketone metabolite, and a carboxy and ketone metabolite. Use 




microsomes (HLM) incubation indicated that a dihydroxy metabolite, carboxy and 
hydroxy metabolites, and a hydroxy and ketone metabolite generated by the fungus were 
also produced by HLM. 
 
The metabolism of the synthetic cannabinoid AM1220 was investigated after incubation 
with HLM and the fungus using liquid chromatography–tandem mass spectrometry (LC-
MS/MS) and LC-HRMS. AM1220 was found to be a high clearance drug and 
hydroxylation, demethylation and dihydrodiol formation were the major 
biotransformations. 
 
The metabolism of acetylfentanyl, acrylfentanyl, 4-fluoro-isobutyrylfentanyl, and 
furanylfentanyl was studied in authentic human urine and human hepatocytes samples 
using LC-HRMS. N-dealkylation, hydroxylation, and hydroxylation and methoxylation 
were the major biotransformations for all but furanylfentanyl, which was mainly 
transformed by amide hydrolysis and dihydrodiol formation. It illustrates the need to 
examine the metabolism of individual drugs rather than predicting them based on the 
previous knowledge. 
 
In conclusion, C. elegans has the ability to mimic human metabolism and, by allowing 
large production of metabolites, enables more comprehensive characterisation of 
metabolites by NMR analysis. Therefore, the fungus can be a useful complementary 
model for metabolism of synthetic cannabinoids. 
